Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $430,749.44 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 30,593 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $14.08, for a total transaction of $430,749.44. Following the completion of the transaction, the insider owned 291,374 shares in the company, valued at approximately $4,102,545.92. The trade was a 9.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Francis Lo also recently made the following trade(s):

• On Thursday, March 5th, Francis Lo sold 38,074 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.09, for a total transaction of $574,536.66.
• On Monday, January 12th, Francis Lo sold 79,590 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $17.73, for a total transaction of $1,411,130.70.
• On Friday, January 2nd, Francis Lo sold 3,125 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.08, for a total transaction of $50,250.00.
• On Monday, December 22nd, Francis Lo sold 4,394 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $17.50, for a total transaction of $76,895.00.
• On Monday, December 15th, Francis Lo sold 113,890 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.57, for a total value of $1,773,267.30.

Adaptive Biotechnologies Stock Up 5.8%

Shares of NASDAQ:ADPT traded up $0.72 during trading on Friday, hitting $13.17. 3,902,529 shares of the company traded hands, compared to its average volume of 1,832,300. The business’s fifty day moving average is $16.55 and its 200-day moving average is $15.85. The stock has a market capitalization of $2.03 billion, a price-to-earnings ratio of -32.92 and a beta of 2.19. Adaptive Biotechnologies Corporation has a one year low of $6.68 and a one year high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The business had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. During the same quarter last year, the business posted ($0.23) EPS. The business’s revenue was up 51.0% on a year-over-year basis. On average, analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Hedge Funds Weigh In On Adaptive Biotechnologies

Large investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd bought a new stake in shares of Adaptive Biotechnologies during the 4th quarter worth about $28,000. Sound Income Strategies LLC acquired a new stake in shares of Adaptive Biotechnologies in the 3rd quarter worth approximately $30,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after acquiring an additional 1,565 shares in the last quarter. Assetmark Inc. increased its stake in shares of Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after acquiring an additional 2,708 shares during the period. Finally, T. Rowe Price Investment Management Inc. acquired a new position in shares of Adaptive Biotechnologies during the fourth quarter valued at approximately $51,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ADPT. JPMorgan Chase & Co. raised their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a research report on Monday, December 1st. They set an “equal weight” rating and a $21.00 price target for the company. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Guggenheim boosted their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, Piper Sandler set a $21.00 target price on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.